Please assess the completion status of the following clinical trial:

Trial Title: Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated informed consent~2. Male or female aged≥ 18 years~3. Senile or pre-senile cataract~4. Scheduled to undergo cataract surgery in a single eyeat a time (clear corneal self-sealing incisions - phacoemulsification - foldable intra-ocular lens surgery with injector)~Exclusion Criteria:~1. Combined surgery~2. Previous intraocular surgery~3. Previous corneal refractive surgeries less than 6 months before screening~4. Non Senile or non pre-senilecataract (e.g.: traumatic, pathological or congenital cataract)~5. Pupillary abnormalities (irregular, etc.)~6. Iris synechiae~7. Eye movement disorder (nystagmus, etc.)~8. Dacryocystitis and all other pathologies of tears drainage system~9. History of Inflammatory ocular disease (Iritis, uveitis, herpetic keratitis)~10. Corneal, epithelial, stromal or endothelial, residual or evolutionary disease (including corneal ulceration and superficial punctuate keratitis)~11. History of ocular traumatism, infection or inflammation within the last 3 months~12. Pseudo-exfoliation, exfoliative syndrome~13. Prior intravitreal injections within 7 days of the surgery~14. IOP over 25mmHg under treatment~15. Best corrected visual acuity \< 1/10~16. Patient already included in the study for phakoexeresis~17. History of ophthalmic surgical complication (cystoid macular oedema, etc.)~18. Diabetes mellitus~19. Surdity~20. Pakinsondisease~21. Excessive anxiety~22. Any other medical or surgical history, disorder or disease such as acute or chronic severe organic disease: hepatic, endocrine neoplasic, hematological diseases, severe psychiatric illness, relevant cardiovascular abnormalities (such as unstable angina, bradycardia, atrial fibrillation,uncontrolled hypertension: systolic blood pressure over 140 mm Hg, diastolic blood pressure over 90 mmHg) and/or any complicating factor or structural abnormality judged by the investigator to be incompatible with the study.~23. Known hypersensitivity to sulfonamides products or any of the components of the study medications or to test products Specific exclusion criteria for women~24. Pregnancy (positive pregnancy test), lactation~25. Women of childbearing potential without an acceptable effective method of contraception (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant) until end of the study participation OR~26. Women not hysterectomized, not menopaused nor surgically sterilized. Exclusion criteria related to general conditions~27. Inability of patient and/or relatives to understand the study procedures and thus inability to give informed consent~28. Non-compliant patient and/or relatives (e.g. not willing to attend the follow-up visits, way of life interfering with compliance)~29. Participation in anotherclinicalstudy~30. Already included once in this study~31. Ward of court~32. Patient not covered by the Social Security

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chloroprocaine 3% (Type: EXPERIMENTAL): All the eligible patients will be administrated by Chloroprocaine 3 % according to the randomization criteria.
- Tetracaine 0.5% (Type: ACTIVE_COMPARATOR): All the eligible patients will be administrated by Tetracaine 0.5% according to the randomization criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete